// App-Quantinova.ai

: First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Researchers

Presenter

  • Nicola Goekbuget

Principal Investigators

  • Andreas Viardot

  • Kathrin Nachtkamp

  • Bjorn Steffen

  • Folker Schneller

  • Nael Alakel

  • Max Topp

  • Boris Boll

  • Christoph Faul

  • Karsten Spiekermann

  • Knut Wendelin

  • Maher Hanoun

  • Ralph Wasch

  • Joachim Beck

  • Sonja Martin

  • Vladan Vucinic

  • Claudia D. Baldus

  • Monika Bruggemann

  • Thomas Burmeister

  • Heike Pfeifer

  • Stefan Schwartz

  • Lena Baumann

  • Diana Tichy

  • Hubert Serve

  • Walter Fiedler

Medical Centers

  • Klinikum Nuernberg, Paracelsus Medizinische Privatuniversität, Nuernberg, Germany

  • Department of Hematology / Oncology, Charité - Universitätsmedizin Berlin, Berlin, Germany

  • Dept. of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

  • Department of Medicine II, Hematology/Oncology, Goethe University, University Hospital, Francenkfurt, Germany

  • Department of Hematology and Oncology, Robert-Bosch-Hospital, Stuttgart, Germany

  • Medical Department III, Klinikum rechts der Isar, Technical University Munich, Munich, Germany

  • Clinic and Policlinic for Hematology and Cellular Therapy, University of Leipzig Medical Center, Leipzig, Germany

  • Medical Department II, Laboratory of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany

  • Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Hospital Eppendorf, Hamburg, Germany

  • Department of Medicine A, Hematology, Oncology and Pneumology, University of Muenster, Muenster, Germany

  • Universitätsmedizin Mainz, Mainz, GERMANY

  • Klinikum der Goethe University, Department of Hematology, Francenkfurt am Main, DEU

  • University of Dresden, Dresden, DEU

  • Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Internal Medicine II, University Hospital and Comprehensive Cancer Center Tübingen, Universitätsklinikum Tübingen, Tübingen, Germany

  • Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany

  • Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany

  • Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany

  • Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany

  • Department of Medicine III, University Hospital, LMU Munich, Munich, Germany

  • Hematology/Oncology, University Hospital Cologne, Cologne, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Lymphomas

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • B-lymphocyte antigen CD20

  • Cyclin-dependent kinase inhibitor 1

  • Histone-lysine N-methyltransferase 2A

  • S-aspartate aminotransferase

  • White Blood Cell

  • Body mass index

Drug/Treatment

  • PEG-asparaginase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Blinatumomab

  • Asparaginase

  • Vincristine

  • Nelarabine

  • Rituximab

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved